Patents by Inventor Michiko Miyamoto

Michiko Miyamoto has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Modified human hepatitis C virus genomic RNA that can be autonomously replicated
    Patent number: 9175269
    Abstract: The present invention provides modified hepatitis C virus genomic RNA, comprising nucleotide sequences of genomic RNA portions of two or more types of hepatitis C viruses, which comprises a 5? untranslated region, a core protein coding sequence, an E1 protein coding sequence, a p7 protein coding sequence, an E2 protein coding sequence, an NS2 protein coding sequence, an NS3 protein coding sequence, an NS4A protein coding sequence, an NS4B protein coding sequence, an NS5A protein coding sequence, an NS5B protein coding sequence, and a 3? untranslated region, and which can be autonomously replicated. In particular, the present invention relates to modified hepatitis C virus genomic RNA, which can be autonomously replicated by substitution of the RNA sequence portion encoding NS3, NS4, NS5A, and NS5B proteins of hepatitis C virus genomic RNA with a partial RNA sequence encoding NS3, NS4, NS5A, and NS5B proteins of a JFH1 strain shown in SEQ ID NO: 1.
    Type: Grant
    Filed: January 4, 2013
    Date of Patent: November 3, 2015
    Assignees: TORAY INDUSTRIES, INC., TOKYO METROPOLITAN INSTITUTE OF MEDICAL SCIENCE
    Inventors: Takaji Wakita, Takanobu Kato, Tomoko Date, Michiko Miyamoto, Ralf Bartenschlager, Jun-ichi Tanabe, Saburo Sone
  • Nucleic acid construct containing full length genome of human hepatitis C virus, recombinant full length virus genome-replicating cells having the nucleic acid construct transferred thereinto and method of producing hepatitis C virus particle
    Patent number: 8460912
    Abstract: The present invention provides a method for replicating efficiently an RNA containing fulllength HCV genomic sequence and a method for producing HCV virus particles containing fulllength HCV replicon RNA or fulllength HCV genomic RNA by using a cell culture system. Further, the present invention relates to a method for producing hepatitis C virus particles which comprises culturing a cell, into which a replicon RNA comprising a nucleotide sequence comprising a fulllength genomic RNA sequence of hepatitis C virus of the genotype 2a, at least one selectable marker gene and/or at least one reporter gene and at least one IRES sequence or the fulllength genomic RNA of hepatitis C virus of the genotype 2a is introduced, and generating virus particles in the culture medium. Still further the present invention relates also to a hepatitis C vaccine and an antibody against hepatitis C virus particles.
    Type: Grant
    Filed: August 21, 2009
    Date of Patent: June 11, 2013
    Assignees: Tokyo Metropolitan Institute of Medical Science, Toray Industries, Inc.
    Inventors: Takaji Wakita, Takanobu Kato, Tomoko Date, Michiko Miyamoto, Jun-ichi Tanabe, Saburo Sone
  • Modified human hepatitis C virus genomic RNA that can be autonomously replicated
    Patent number: 8454973
    Abstract: The present invention provides modified hepatitis C virus genomic RNA, comprising nucleotide sequences of genomic RNA portions of two or more types of hepatitis C viruses, which comprises a 5? untranslated region, a core protein coding sequence, an E1 protein coding sequence, a p7 protein coding sequence, an E2 protein coding sequence, an NS2 protein coding sequence, an NS3 protein coding sequence, an NS4A protein coding sequence, an NS4B protein coding sequence, an NS5A protein coding sequence, an NS5B protein coding sequence, and a 3? untranslated region, and which can be autonomously replicated. In particular, the present invention relates to modified hepatitis C virus genomic RNA, which can be autonomously replicated by substitution of the RNA sequence portion encoding NS3, NS4, NS5A, and NS5B proteins of hepatitis C virus genomic RNA with a partial RNA sequence encoding NS3, NS4, NS5A, and NS5B proteins of a JFH1 strain shown in SEQ ID NO: 1.
    Type: Grant
    Filed: August 24, 2005
    Date of Patent: June 4, 2013
    Assignees: Tokyo Metropolitan Institute of Medical Science, Toray Industries, Inc.
    Inventors: Takaji Wakita, Takanobu Kato, Tomoko Date, Michiko Miyamoto, Ralf Bartenschlager, Jun-ichi Tanabe, Saburo Sone
  • Nucleic acid and gene derived from novel HCV strain and replicon-replicating cell using said gene
    Patent number: 8022197
    Abstract: The present invention relates to a gene derived from a novel fulminant hepatitis C virus strain, an HCV replicon RNA with a high replication efficiency obtained using the gene, and an HCV replicon-replicating cell transfected with the replicon RNA. When the HCV replicon RNA and the HCV replicon-replicating cell of the present invention are used, HCV proteins can be continuously produced in a large amount.
    Type: Grant
    Filed: September 16, 2004
    Date of Patent: September 20, 2011
    Assignees: Tokyo Metropolitan Organization for Medical Research, Toray Industries Inc.
    Inventors: Takaji Wakita, Takanobu Kato, Tomoko Date, Michiko Miyamoto
  • Nucleic acid and gene derived from novel HCV strain and replicon-replicating cell using said gene
    Patent number: 7790448
    Abstract: The present invention relates to a gene derived from a novel fulminant hepatitis C virus strain, an HCV replicon RNA with a high replication efficiency obtained using the gene, and an HCV replicon-replicating cell transfected with the replicon RNA. When the HCV replicon RNA and the HCV replicon-replicating cell of the present invention are used, HCV proteins can be continuously produced in a large amount.
    Type: Grant
    Filed: September 12, 2007
    Date of Patent: September 7, 2010
    Assignees: Tokyo Metropolitan Organization for Medical Research, Toray Industries, Inc.
    Inventors: Takaji Wakita, Takanobu Kato, Tomoko Date, Michiko Miyamoto
  • Nucleic acid construct containing full length genome of human hepatitis C virus, recombinant full length virus genome-replicating cells having the nucleic acid construct transferred thereinto and method of producing hepatitis C virus particle
    Publication number: 20100047896
    Abstract: The present invention provides a method for replicating efficiently an RNA containing fulllength HCV genomic sequence and a method for producing HCV virus particles containing fulllength HCV replicon RNA or fulllength HCV genomic RNA by using a cell culture system. Further, the present invention relates to a method for producing hepatitis C virus particles which comprises culturing a cell, into which a replicon RNA comprising a nucleotide sequence comprising a fulllength genomic RNA sequence of hepatitis C virus of the genotype 2a, at least one selectable marker gene and/or at least one reporter gene and at least one IRES sequence or the fulllength genomic RNA of hepatitis C virus of the genotype 2a is introduced, and generating virus particles in the culture medium. Still further the present invention relates also to a hepatitis C vaccine and an antibody against hepatitis C virus particles.
    Type: Application
    Filed: August 21, 2009
    Publication date: February 25, 2010
    Applicants: Tokyo Metropolitan Organization for Medical Research, TORAY INDUSTRIES, INC.
    Inventors: Takaji Wakita, Takanobu Kato, Tomoko Date, Michiko Miyamoto, Jun-ichi Tanabe, Saburo Sone
  • Nucleic acid construct containing fulllength genome of human hepatitis C virus, recombinant fulllength virus genome-replicating cells having the nucleic acid construct transferred thereinto and method of producing hepatitis C virus Particle
    Patent number: 7659103
    Abstract: The present invention provides a method for replicating efficiently an RNA containing fulllength HCV genomic sequence and a method for producing HCV virus particles containing fulllength HCV replicon RNA or fulllength HCV genomic RNA by using a cell culture system. Further, the present invention relates to a method for producing hepatitis C virus particles which comprises culturing a cell, into which a replicon RNA comprising a nucleotide sequence comprising a fulllength genomic RNA sequence of hepatitis C virus of the genotype 2a, at least one selectable marker gene and/or at least one reporter gene and at least one IRES sequence or the fulllength genomic RNA of hepatitis C virus of the genotype 2a is introduced, and generating virus particles in the culture medium. Still further the present invention relates also to a hepatitis C vaccine and an antibody against hepatitis C virus particles.
    Type: Grant
    Filed: February 21, 2005
    Date of Patent: February 9, 2010
    Assignees: Tokyo Metropolitan Organization For Medical Research, Toray Industries, Inc.
    Inventors: Takaji Wakita, Takanobu Kato, Tomoko Date, Michiko Miyamoto, Jun-ichi Tanabe, Saburo Sone
  • Modified Human Hepatitis C Virus Genomic RNA That can be Autonomously Replicated
    Publication number: 20090176200
    Abstract: The present invention provides modified hepatitis C virus genomic RNA, comprising nucleotide sequences of genomic RNA portions of two or more types of hepatitis C viruses, which comprises a 5? untranslated region, a core protein coding sequence, an E1 protein coding sequence, a p7 protein coding sequence, an E2 protein coding sequence, an NS2 protein coding sequence, an NS3 protein coding sequence, an NS4A protein coding sequence, an NS4B protein coding sequence, an NS5A protein coding sequence, an NS5B protein coding sequence, and a 3? untranslated region, and which can be autonomously replicated. In particular, the present invention relates to modified hepatitis C virus genomic RNA, which can be autonomously replicated by substitution of the RNA sequence portion encoding NS3, NS4, NS5A, and NS5B proteins of hepatitis C virus genomic RNA with a partial RNA sequence encoding NS3, NS4, NS5A, and NS5B proteins of a JFH1 strain shown in SEQ ID NO: 1.
    Type: Application
    Filed: August 24, 2005
    Publication date: July 9, 2009
    Inventors: Takaji Wakita, Takanobu Kato, Tomoko Date, Michiko Miyamoto, Ralf Bartenschlager, Jun-ichi Tanabe, Saburo Sone
  • Nucleic acid and gene derived from novel HCV strain and replicon-replicating cell using said gene
    Publication number: 20090042181
    Abstract: The present invention relates to a gene derived from a novel fulminant hepatitis C virus strain, an HCV replicon RNA with a high replication efficiency obtained using the gene, and an HCV replicon-replicating cell transfected with the replicon RNA. When the HCV replicon RNA and the HCV replicon-replicating cell of the present invention are used, HCV proteins can be continuously produced in a large amount.
    Type: Application
    Filed: September 12, 2007
    Publication date: February 12, 2009
    Applicants: Tokyo Metropolitan Organization for Medical Research, TORAY INDUSTRIES, INC.
    Inventors: Takaji Wakita, Takanobu Kato, Tomoko Date, Michiko Miyamoto
  • Nucleic Acid and Gene Derived from Novel HCV Strain and Replicon-Replicating Cell Using Said Gene
    Publication number: 20090035747
    Abstract: The present invention relates to a gene derived from a novel fulminant hepatitis C virus strain, an HCV replicon RNA with a high replication efficiency obtained using the gene, and an HCV replicon-replicating cell transfected with the replicon RNA. When the HCV replicon RNA and the HCV replicon-replicating cell of the present invention are used, HCV proteins can be continuously produced in a large amount.
    Type: Application
    Filed: September 16, 2004
    Publication date: February 5, 2009
    Inventors: Takaji Wakita, Takanobu Kato, Tomoko Date, Michiko Miyamoto
  • Nucleic Acid Construct Containing Fulllength Genome of Human Hepatitis C Virus, Recombinant Fulllength Virus Genome-Replicating Cells Having the Nucleic Acid Construct Transferred Thereinto and Method of Producing Hepatitis C Virus Particle
    Publication number: 20080220019
    Abstract: The present invention provides a method for replicating efficiently an RNA containing fulllength HCV genomic sequence and a method for producing HCV virus particles containing fulllength HCV replicon RNA or fulllength HCV genomic RNA by using a cell culture system. Further, the present invention relates to a method for producing hepatitis C virus particles which comprises culturing a cell, into which a replicon RNA comprising a nucleotide sequence comprising a fulllength genomic RNA sequence of hepatitis C virus of the genotype 2a, at least one selectable marker gene and/or at least one reporter gene and at least one IRES sequence or the fulllength genomic RNA of hepatitis C virus of the genotype 2a is introduced, and generating virus particles in the culture medium. Still further the present invention relates also to a hepatitis C vaccine and an antibody against hepatitis C virus particles.
    Type: Application
    Filed: February 21, 2005
    Publication date: September 11, 2008
    Applicants: Tokyo Metropolitan Organization for Medical Research, Toray Industries, Inc.
    Inventors: Takaji Wakita, Takanobu Kato, Tomoko Date, Michiko Miyamoto, Jun-ichi Tanabe, Saburo Sone